AstraZeneca releases more data on its Covid-19 vaccine
AstraZeneca PLC released more pivotal trial data for its Covid-19 vaccine, claiming the vaccine was 76% effective at preventing Covid-19 with symptoms in a more comprehensive analysis of study results than the company had previously provided.
AstraZeneca said its latest vaccine effectiveness figures were based on an analysis of 190 symptomatic Covid-19 cases in the trial, 49 more cases than the company had previously analyzed.
Despite the additional cases, the vaccine’s performance was in line with what AstraZeneca first reported.
An independent study oversight committee said the data was out of date, prompting the U.S. National Institute of Allergy and Infectious Diseases to issue an unusual statement raising concerns from experts.